Patient characteristics by FOXP1 expression status
| . | BCCA . | GLSG . | ||||||
|---|---|---|---|---|---|---|---|---|
| Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . | Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . | |
| Age ≤60 y | 142 | 29 (44) | 41 (54) | 395 | 45 (31) | 67 (27) | ||
| Age >60 y | 37 (56) | 35 (46) | .245 | 102 (69) | 181 (73) | .42 | ||
| ECOG ≤1 | 140 | 54 (83) | 68 (91) | 389 | 138 (95) | 225 (93) | ||
| ECOG >1 | 11 (17) | 7 (9) | .100 | 8 (5) | 18 (7) | .60 | ||
| Stage I | 142 | 1 (2) | 1 (1) | .837 | 393 | — | — | <.001 |
| Stage II | 6 (9) | 6 (8) | — | — | ||||
| Stage III | 25 (38) | 24 (32) | 66 (45) | 68 (28) | ||||
| Stage IV | 34 (52) | 45 (59) | 81 (65) | 178 (72) | ||||
| No. of nodal sites ≤4 | 140 | 18 (28) | 16 (21) | 380 | 57 (40) | 54 (23) | ||
| No. of nodal sites >4 | 47 (72) | 59 (79) | .432 | 87 (60) | 182 (77) | <.001 | ||
| LDH normal | 135 | 55 (89) | 53 (73) | 387 | 112 (78) | 161 (66) | ||
| LDH elevated | 7 (11) | 20 (27) | .030 | 32 (22) | 82 (34) | .022 | ||
| Hemoglobin ≥120 g/L | 138 | 6 (9) | 10 (14) | 387 | 125 (86) | 181 (72) | ||
| Hemoglobin <120 g/L | 58 (81) | 64 (86) | .596 | 21 (14) | 70 (28) | .020 | ||
| FLIPI low/intermediate | 138 | 32 (49) | 36 (49) | 383 | 96 (67) | 110 (46) | ||
| FLIPI high | 33 (51) | 37 (51) | 1.000 | 47 (33) | 130 (54) | <.001 | ||
| m7-FLIPI low | 107 | 44 (85) | 39 (71) | 87 | 22 (81) | 41 (68) | ||
| m7-FLIPI high | 8 (15) | 16 (29) | .108 | 5 (19) | 19 (32) | .312 | ||
| R-chemotherapy* | 142 | 66 (100) | 76 (100) | 395 | 72 (49) | 132 (53) | ||
| Chemotherapy* | — | — | N/A | 75 (51) | 116 (47) | .48 | ||
| R maintenance | 142 | 57 (86) | 60 (79) | 395 | — | — | ||
| No R maintenance | 9 (14) | 16 (21) | .276 | 147 (100) | 248 (100) | N/A | ||
| . | BCCA . | GLSG . | ||||||
|---|---|---|---|---|---|---|---|---|
| Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . | Evaluable . | FOXP1 low, n (%) . | FOXP1 high, n (%) . | P . | |
| Age ≤60 y | 142 | 29 (44) | 41 (54) | 395 | 45 (31) | 67 (27) | ||
| Age >60 y | 37 (56) | 35 (46) | .245 | 102 (69) | 181 (73) | .42 | ||
| ECOG ≤1 | 140 | 54 (83) | 68 (91) | 389 | 138 (95) | 225 (93) | ||
| ECOG >1 | 11 (17) | 7 (9) | .100 | 8 (5) | 18 (7) | .60 | ||
| Stage I | 142 | 1 (2) | 1 (1) | .837 | 393 | — | — | <.001 |
| Stage II | 6 (9) | 6 (8) | — | — | ||||
| Stage III | 25 (38) | 24 (32) | 66 (45) | 68 (28) | ||||
| Stage IV | 34 (52) | 45 (59) | 81 (65) | 178 (72) | ||||
| No. of nodal sites ≤4 | 140 | 18 (28) | 16 (21) | 380 | 57 (40) | 54 (23) | ||
| No. of nodal sites >4 | 47 (72) | 59 (79) | .432 | 87 (60) | 182 (77) | <.001 | ||
| LDH normal | 135 | 55 (89) | 53 (73) | 387 | 112 (78) | 161 (66) | ||
| LDH elevated | 7 (11) | 20 (27) | .030 | 32 (22) | 82 (34) | .022 | ||
| Hemoglobin ≥120 g/L | 138 | 6 (9) | 10 (14) | 387 | 125 (86) | 181 (72) | ||
| Hemoglobin <120 g/L | 58 (81) | 64 (86) | .596 | 21 (14) | 70 (28) | .020 | ||
| FLIPI low/intermediate | 138 | 32 (49) | 36 (49) | 383 | 96 (67) | 110 (46) | ||
| FLIPI high | 33 (51) | 37 (51) | 1.000 | 47 (33) | 130 (54) | <.001 | ||
| m7-FLIPI low | 107 | 44 (85) | 39 (71) | 87 | 22 (81) | 41 (68) | ||
| m7-FLIPI high | 8 (15) | 16 (29) | .108 | 5 (19) | 19 (32) | .312 | ||
| R-chemotherapy* | 142 | 66 (100) | 76 (100) | 395 | 72 (49) | 132 (53) | ||
| Chemotherapy* | — | — | N/A | 75 (51) | 116 (47) | .48 | ||
| R maintenance | 142 | 57 (86) | 60 (79) | 395 | — | — | ||
| No R maintenance | 9 (14) | 16 (21) | .276 | 147 (100) | 248 (100) | N/A | ||
Bold values indicate statistical significance.
ECOG, Eastern Cooperative Oncology Group performance status; N/A, not applicable; R, rituximab.
Chemotherapy refers to CVP for BCCA patients and CHOP for GLSG patients.